Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 8, 2011, Pages 3406-3411

  Patel, Anand G ^a   Sarkaria, Jann N ^b   Kaufmann, Scott H ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Chemotherapy; DNA repair; Double strand break repair; Synthetic lethality

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ATM PROTEIN; AZ 12594248; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; DNA DEPENDENT PROTEIN KINASE; ETOPOSIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; VELIPARIB;

ARTICLE; CANCER CELL CULTURE; CELL DAMAGE; CONTROLLED STUDY; CYTOTOXICITY; DEREGULATION; DOWN REGULATION; ENZYME INHIBITION; ENZYME SUBSTRATE; GENETIC PARAMETERS; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; LETHALITY; MALE; NONHOMOLOGOUS END JOINING; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL;

ANIMALS; CELL DEATH; CELL LINE; DNA REPAIR; DNA-ACTIVATED PROTEIN KINASE; ENZYME INHIBITORS; GENOMIC INSTABILITY; MICE; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; RECOMBINATION, GENETIC;

EID: 79952747328     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1013715108     Document Type: Article

References (46)

1. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293-301.
2. Ferraris DV (2010) Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem 53:4561-4584.
3. Bryant HE, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917. (Pubitemid 40559005)
4. Farmer H, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921. (Pubitemid 40559006)
5. Mendes-Pereira AM, et al. (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1:315-322.
6. Sourisseau T, et al. (2010) Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO Mol Med 2:130-142.
7. Williamson CT, et al. (2010) ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 9:347-357.
8. Weston VJ, et al. (2010) The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116:4578-4587.
9. Weterings E, Chen DJ (2008) The endless tale of non-homologous end-joining. Cell Res 18:114-124.
10. Pace P, et al. (2010) Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. Science 329:219-223.
11. Adamo A, et al. (2010) Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. Mol Cell 39:25-35.
12. Galande S, Kohwi-Shigematsu T (1999) Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences. J Biol Chem 274:20521-20528.
13. Pleschke JM, Kleczkowska HE, Strohm M, Althaus FR (2000) Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J Biol Chem 275:40974-40980. (Pubitemid 32054922)
14. Li B, Navarro S, Kasahara N, Comai L (2004) Identification and biochemical characterization of a Werner's syndrome protein complex with Ku70/80 and poly (ADP-ribose) polymerase-1. J Biol Chem 279:13659-13667. (Pubitemid 38468894)
15. Gagné J-P, et al. (2008) Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res 36:6959-6976.
16. Wang M, et al. (2006) PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 34:6170-6182. (Pubitemid 44942738)
17. Hochegger H, et al. (2006) Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J 25:1305-1314.
18. Saberi A, et al. (2007) RAD18 and poly(ADP-ribose) polymerase independently suppress the access of nonhomologous end joining to double-strand breaks and facilitate homologous recombination-mediated repair. Mol Cell Biol 27:2562-2571. (Pubitemid 46581347)
19. Caldecott KW (2003) XRCC1 and DNA strand break repair. DNA Repair(Amst) 2:955-969.
20. Sakai W, et al. (2009) Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 69:6381-6386.
21. Gottipati P, et al. (2010) Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 70:5389-5398.
22. Penning TD, et al. (2009) Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 52:514-523.
23. Chan DW, et al. (2002) Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev 16:2333-2338. (Pubitemid 35034402)
24. Stiff T, et al. (2004) ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 64:2390-2396. (Pubitemid 38523891)
25. Hingorani M, et al. (2008) Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res 68:9771-9778.
26. Hickson I, et al. (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64:9152-9159. (Pubitemid 39665530)
27. Uematsu N, et al. (2007) Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaks. J Cell Biol 177:219-229. (Pubitemid 46658634)
28. Ma Y, Pannicke U, Schwarz K, Lieber MR (2002) Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 108:781-794. (Pubitemid 34327530)
29. Drouet J, et al. (2006) Interplay between Ku, Artemis, and the DNA-dependent protein kinase catalytic subunit at DNA ends. J Biol Chem 281:27784-27793. (Pubitemid 44418983)
30. Seluanov A, Mittelman D, Pereira-Smith OM, Wilson JH, Gorbunova V (2004) DNA end joining becomes less efficient and more error-prone during cellular senescence. Proc Natl Acad Sci USA 101:7624-7629. (Pubitemid 38658079)
31. Fattah F, et al. (2010) Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells. PLoS Genet 6:e1000855.
32. Wang H, et al. (2003) Biochemical evidence for Ku-independent backup pathways of NHEJ. Nucleic Acids Res 31:5377-5388. (Pubitemid 37441906)
33. Verkaik NS, et al. (2002) Different types of V(D)J recombination and end-joining defects in DNA double-strand break repair mutant mammalian cells. Eur J Immunol 32:701-709. (Pubitemid 34257548)
34. Bunting SF, et al. (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141:243-254.
35. Goggins M, et al. (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360-5364. (Pubitemid 27011364)
36. Tomlinson GE, et al. (1998) Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 58:3237-3242. (Pubitemid 28371058)
37. Ziv Y, et al. (1997) Recombinant ATM protein complements the cellular A-T phenotype. Oncogene 15:159-167. (Pubitemid 27344555)
38. Orsburn B, et al. (2010) Differential requirement for H2AX and 53BP1 in organismal development and genome maintenance in the absence of poly(ADP)ribosyl polymerase 1. Mol Cell Biol 30:2341-2352.
39. FitzGerald JE, Grenon M, Lowndes NF (2009) 53BP1: Function and mechanisms of focal recruitment. Biochem Soc Trans 37:897-904.
40. Bouwman P, et al. (2010) 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17:688-695.
41. Audeh MW, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 376:245-251.
42. Tutt A, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 376:235-244.
43. Chan SL, Mok T (2010) PARP inhibition in BRCA-mutated breast and ovarian cancers. Lancet 376:211-213.
44. Karnitz LM, et al. (2005) Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68:1636-1644. (Pubitemid 41654347)
45. Fletcher J (2001) Metaphase harvest and cytogenetic analysis of solid tumor cultures. Current Protocols in Human Genetics (Wiley, New York), pp 10.3.1-10.3.10.
46. Hashimoto H, Chatterjee S, Berger NA (1995) Mutagenic activity of topoisomerase I inhibitors. Clin Cancer Res 1:369-376.